EP2606936A2 - Soin capillaire avec un émulsifiant spécial et des hydrolysats protéiques - Google Patents

Soin capillaire avec un émulsifiant spécial et des hydrolysats protéiques Download PDF

Info

Publication number
EP2606936A2
EP2606936A2 EP12191940.1A EP12191940A EP2606936A2 EP 2606936 A2 EP2606936 A2 EP 2606936A2 EP 12191940 A EP12191940 A EP 12191940A EP 2606936 A2 EP2606936 A2 EP 2606936A2
Authority
EP
European Patent Office
Prior art keywords
oil
und
acid
polyquaternium
oder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12191940.1A
Other languages
German (de)
English (en)
Other versions
EP2606936A3 (fr
EP2606936B1 (fr
Inventor
Marlene Battermann
Christin MÜLLER-VON BORSTEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henkel AG and Co KGaA
Original Assignee
Henkel AG and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel AG and Co KGaA filed Critical Henkel AG and Co KGaA
Publication of EP2606936A2 publication Critical patent/EP2606936A2/fr
Publication of EP2606936A3 publication Critical patent/EP2606936A3/fr
Application granted granted Critical
Publication of EP2606936B1 publication Critical patent/EP2606936B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers

Definitions

  • the invention relates to hair treatment compositions containing PEG-30 dipolyhydroxystearates and protein hydrolysates and the use of these agents for hair treatment.
  • hair treatment compositions comprising PEG-30 dipolyhydroxystearates and protein hydrolysates, in particular in the further presence of selected quaternary compounds, lead to stable active compositions and can be formulated as W / O emulsions.
  • the use of these combinations leads to surprisingly good properties of the treated keratinic fibers, in particular to a significantly improved gloss and increased durability of the care performance and the gloss over several hair washes away.
  • the enhanced care benefits include improved combability, improved hair texture, improved elasticity, as well as significantly enhanced washfastness of dyed hair, as well as longer shelf life while providing improved forming performance in corrugations such as water wave and perm.
  • composition of the invention in addition to the classic cream formulations, is also suitable for spray application both as a non-aerosol and as an aerosol.
  • spray application both as a non-aerosol and as an aerosol.
  • an extremely uniform spray pattern is achieved compared to the usual products.
  • the entire composition is distributed very evenly on the hair.
  • Hair treatment compositions in the context of the present invention are, for example, hair conditioners, hair sprays, hair rinses, hair treatments, hair wraps, hair tonics, hair fixatives, hair dressings, hair styling preparations, hair waving lotions, mousses, hair gels, hair waxes or combinations thereof.
  • Preferred agents according to the invention are conditioning agents or hair tonics.
  • the agents according to the invention are in the form of a W / O emulsion.
  • combing is understood according to the invention both the combability of the wet fiber, as well as the combability of the dry fiber. As a measure of the combing used the combing work or the force used during the combing process of a fiber collective. The measurement parameters can be assessed by the skilled person or quantified by measuring devices.
  • the grip defines the tactility of a fiber collective, whereby the expert sensoryly senses and evaluates the parameters fullness and suppleness of the collective.
  • Shaping is understood to mean the ability to give a shape change to a group of previously treated keratin-containing fibers, in particular human hair. Hair cosmetics also speak of hair styling.
  • the cosmetic carrier c) according to the invention is a W / O or W / O / W emulsions in the form of creams or gels or other preparations which are particularly suitable for use on the hair.
  • the cosmetic carriers may in particular be aqueous or aqueous-alcoholic.
  • An aqueous cosmetic carrier contains at least 50% by weight of water.
  • aqueous-alcoholic cosmetic carriers include aqueous solutions containing 3 to 70% by weight of a C 1 -C 6 -alcohol, in particular methanol, ethanol or propanol, isopropanol, butanol, isobutanol, tert-butanol, n-Pentanol, iso-pentanols, n-hexanol, iso-hexanols, glycol, glycerol, 1,2-pentanediol, 1,5-pentanediol, 1,2-hexanediol or 1,6-hexanediol to understand.
  • the compositions according to the invention may additionally contain further organic solvents, for example methoxybutanol, benzyl alcohol, ethyl diglycol or 1,2-propylene glycol. Preference is given to all water-soluble organic solvents.
  • Ingredient a) is PEG-30 dipolyhydroxystearate. This compound is included in the cosmetic compositions in a total amount of from 0.01 to 5.0% by weight, preferably from 0.01 to 4.0% by weight, more preferably from 0.05 to 3.5% by weight, and most preferably 0.05 to 3.0 wt.%, In each case based on the total composition used.
  • the second essential ingredient b) in the active ingredient complex according to the invention are protein hydrolysates and / or derivatives thereof.
  • protein hydrolysates of both vegetable and animal or marine or synthetic origin can be used.
  • Animal protein hydrolysates are, for example, elastin, collagen, keratin, silk and milk protein protein hydrolysates, which may also be in the form of salts.
  • Such products are, for example, under the trademarks Dehylan ® (Cognis), Promois® ® (Interorgana) Collapuron ® (Cognis), Nutrilan® ® (Cognis), Gelita-Sol ® (German Gelatinefabriken Stoess & Co), Lexein ® (Inolex) and kerasol tm ® (Croda) sold.
  • Further preferred vegetable protein hydrolysates according to the invention are, for example, soya, almond, pea, potato and wheat protein hydrolysates.
  • Such products are, for example, under the trademarks Gluadin ® (Cognis), diamine ® (Diamalt) ® (Inolex), Hydrosoy ® (Croda), hydro Lupine ® (Croda), hydro Sesame ® (Croda), Hydro tritium ® (Croda) and Crotein ® (Croda) available.
  • protein hydrolysates according to the invention are of maritime origin. These include, for example, collagen hydrolyzates of fish or algae as well as protein hydrolysates of mussels or pearl hydrolyzates.
  • pearl extracts according to the invention are the commercial products Pearl Protein Extract BG ® or Crodarom ® Pearl.
  • protein hydrolysates based on collagen, silk, keratin, milk protein, soy, almonds, wheat, fish, algae or pearls Most preferred are the hydrolysates based on silk, keratin, milk protein, fish, algae or pearls.
  • An example of a particularly suitable protein hydrolyzate according to the invention is available from Croda under the trade name ProSina®.
  • the protein hydrolysates are present in the compositions at levels of from 0.001% to 10% by weight, preferably from 0.001% to 7.5% by weight, most preferably from 0.01% to 5% by weight % By weight, most preferably in amounts of from 0.01 up to 3.0% by weight and most preferably in amounts of from 0.05 to 2.0% by weight.
  • the effect is further enhanced by the presence of a selected compound having a quaternary ammonium group.
  • Quaternary ammonium compounds are in principle monomeric cationic or amphoteric ammonium compounds, monomeric amines, aminoamides, polymeric cationic ammonium compounds and polymeric amphoteric ammonium compounds. From these many possible quaternary ammonium compounds, the following groups have been found to be particularly suitable and are taken in each case in an amount of 0.1 to 10.0 wt.%. This amount is also not exceeded or exceeded when a mixture of different compounds of the quaternary ammonium compounds is used.
  • the rest - (X - R4) is contained at least 1 to 3 times.
  • Such products are marketed under the trademarks Rewoquat ®, Stepantex® ®, Dehyquart® ®, ® and Armocare® Akypoquat ®.
  • the products Armocare ® VGH-70, Dehyquart ® F-75, Dehyquart ® C-4046, Dehyquart ® L80, Dehyquart ® F-30, Dehyquart ® AU-35, Rewoquat ® WE18, Rewoquat ® WE38 DPG, Stepantex ® VS 90 and Akypoquat ® 131 are examples of these esterquats.
  • R8 corresponds in its meaning R7.
  • esterquats with tradenames Armocare ® VGH-70 are, as well as Dehyquart ® F-75, Dehyquart ® L80, Stepantex ® VS 90 and Akypoquat ® 131st
  • Tkat2 Another group are quaternary imidazoline compounds.
  • the formula (Tkat2) shown below shows the structure of these compounds.
  • the radicals R independently of one another each represent a saturated or unsaturated, linear or branched hydrocarbon radical having a chain length of 8 to 30 carbon atoms.
  • the preferred compounds of the formula (Tkat2) contain for R the same hydrocarbon radical.
  • the chain length of the radicals R is preferably 12 to 21 carbon atoms.
  • A is an anion as previously described. Examples according to the invention are available, for example, under the INCII names Quaternium-27, Quaternium-72, Quaternium-83 and Quaternium-91. Quaternium-91 is most preferred according to the invention.
  • A is an anion as previously described and n is an integer between 1 and 10.
  • R1 is a branched or unbranched, saturated or unsaturated acyl radical having 6 to 30 C atoms, which may contain at least one OH group means.
  • amidoamines and / or quaternized amidoamines in which R 2, R 3 and / or R 4 in the formula (Tkat3) represent a radical according to the general formula CH 2 CH 2 OR 5, where R 5 is the meaning of alkyl radicals having 1 to 4 carbon atoms , Hydroxyethyl or hydrogen.
  • the preferred size of n in the general formula (Tkat8) is an integer between 2 and 5.
  • the alkylamidoamines can both be present as such and converted by protonation in a correspondingly acidic solution into a quaternary compound in the composition. According to the invention, the cationic alkylamidoamines are preferred.
  • Witcamine ® 100 Incromine ® BB, Mackine ® 401 and other Mackine ® grades, Adogen ® S18V, and as a permanent cationic aminoamines: Rewoquat ® RTM 50, Empigen ® CSC, Swanol ® Lanoquat DES-50, Rewoquat ® UTM 50, Schercoquat® ® BAS ® Lexquat AMG-BEO, or Incroquat ® behenyl HE.
  • ammonium halides in particular chlorides and bromides, such as alkyltrimethylammonium chlorides, dialkyldimethylammonium chlorides and trialkylmethylammonium chlorides, for example cetyltrimethylammonium chloride, stearyltrimethylammonium chloride, behenyltrimethylammonium chloride, distearyldimethylammonium chloride, lauryldimethylammonium chloride, Lauryldimethylbenzylammonium chloride and tricetylmethylammonium chloride.
  • the long alkyl chains of the above-mentioned surfactants preferably have 10 to 22 carbon atoms.
  • the abovementioned cationic surfactants can be used individually or in any desired combinations with one another, with amounts of from 0.01 to 10% by weight, preferably from 0.01 to 7.5% by weight, and very particularly preferably from 0 to 0, 1 to 5.0% by weight. The very best results are obtained with amounts of from 0.1 to 3.0% by weight, based in each case on the total composition of the particular agent.
  • quaternary ammonium compounds are cationic and amphoteric polymers.
  • the cationic and / or amphoteric polymers may be homopolymers or copolymers or polymers based on natural polymers, wherein the quaternary nitrogen groups are contained either in the polymer chain or preferably as a substituent on one or more of the monomers.
  • the ammonium group-containing monomers may be copolymerized with non-cationic monomers.
  • Suitable cationic monomers are unsaturated, radically polymerizable compounds bearing at least one cationic group, especially ammonium substituted vinyl monomers such as trialkylmethacryloxyalkylammonium, trialkylacryloxyalkylammonium, dialkyldiallylammonium and quaternary vinylammonium monomers having cyclic cationic nitrogen containing groups such as pyridinium, imidazolium or quaternary pyrrolidones, e.g. Alkylvinylimidazolium, Alkylvinylpyridinium, or Alyklvinylpyrrolidon salts.
  • the alkyl groups of these monomers are preferably lower alkyl groups such as C1 to C7 alkyl groups, more preferably C1 to C3 alkyl groups.
  • the ammonium group-containing monomers may be copolymerized with non-cationic monomers.
  • Suitable comonomers are, for example, acrylamide, methacrylamide; Alkyl and dialkylacrylamide, alkyl and dialkylmethacrylamide, alkylacrylate, alkylmethacrylate, vinylcaprolactone, vinylcaprolactam, vinylpyrrolidone, vinylester, e.g. Vinyl acetate, vinyl alcohol, propylene glycol or ethylene glycol, wherein the alkyl groups of these monomers are preferably C1 to C7 alkyl groups, more preferably C1 to C3 alkyl groups.
  • X - is a physiologically acceptable organic or inorganic anion.
  • R 1 is a methyl group
  • R 2 , R 3 and R 4 are methyl groups
  • m is 2.
  • physiologically compatible counterions X - come, for example, halide ions, sulfate ions, phosphate ions, Methosulfationen and organic ions such as lactate, citrate, tartrate and acetate ions. Preference is given to methosulfates and halide ions, in particular chloride.
  • Suitable cationic polymers which are derived from synthetic polymers are, for example, copolymers A from A1) from 0.1 to 50%, preferably from 10 to 50% (based on the total number of monomers in the copolymer) of monomers of the formula (Ia) in the X is chloride, sulfate, methosulfate, and A2) monomers from the group of acrylic acid, methacrylic acid and the alkali metal and ammonium salts of these acids, wherein the monomer A2 50 to 99.9%, preferably 50 to 90% (based on the Total number of monomers in the copolymer) of the copolymer; contain.
  • a most preferred polymer constructed as previously shown is commercially available under the name Polyquaternium-74.
  • a particularly suitable homopolymer is, if desired, crosslinked, poly (methacryloyloxyethyltrimethylammonium chloride) with the INCI name Polyquaternium-37.
  • poly methacryloyloxyethyltrimethylammonium chloride
  • Rheocare ® CTH Cosmetic Rheologies
  • Synthalen® ® CR 3V Sigma
  • the homopolymer is preferably used in the form of a non-aqueous polymer dispersion.
  • Such polymer dispersions are available under the names Salcare ® SC 95 and Salcare ® SC 96 in the trade.
  • Suitable cationic polymers derived from natural polymers are cationic derivatives of polysaccharides, for example, cationic derivatives of cellulose, starch or guar. Also suitable are chitosan and chitosan derivatives. Cationic polysaccharides have the general formula GOB-N + R a R b R c A -
  • G is an anhydroglucose residue, for example starch or cellulose anhydroglucose
  • B is a divalent linking group, for example, alkylene, oxyalkylene, polyoxyalkylene or hydroxyalkylene;
  • R a , R b and R c are independently alkyl, aryl, alkylaryl, arylalkyl, alkoxyalkyl or alkoxyaryl each having up to 18 carbon atoms, wherein the total number of carbon atoms in R a , R b and R c is preferably not more than 20 is;
  • a - is a common counteranion and is preferably chloride.
  • Cationic, ie quaternized celluloses are available on the market with varying degrees of substitution, cationic charge density, nitrogen content and molecular weights.
  • Polyquaternium-67 is commercially available under the designations SL ® polymer or polymer ® SK (Amerchol) is. Under the trade designation Mirustyle CP ® of the company. Croda another most preferred cellulose is available. This is a trimonium and Cocodimonium hydroxyethylcellulose as derivatized cellulose with the INCI name Polyquaternium-72. Polyquaternium-72 can be used pre-dissolved both in solid form and already in aqueous solution.
  • cationic celluloses are, 400 (Amerchol, INCI name Polyquaternium-10) and polymer Quatrisoft ® LM-200 (Amerchol, INCI name Polyquaternium-24) under the names Polymer JR ®.
  • Other commercial products the compounds Celquat ® H 100 and Celquat ® L are 200.
  • Mirustyle CP ® of the company Croda with Trimonium and Cocodimonium hydroxyethylcellulose a further derivatized cellulose with the INCI name Polyquaternium-72 before.
  • Polyquaternium-72 can be used pre-dissolved both in solid form and already in aqueous solution.
  • Particularly preferred cationic celluloses are Polyquaternium-10, Polyquaternium-24, Polyquaternium-67 and Polyquaternium-72.
  • Suitable cationic guar derivatives are marketed under the trade name Jaguar ® and have the INCI name guar hydroxypropyltrimonium chloride. Also particularly suitable cationic guar derivatives also by the company. Hercules under the name N-Hance ® commercially. Other cationic guar derivatives are marketed by the company. Cognis under the name Cosmedia® ®. A preferred cationic guar derivative is the commercial product AquaCat® ® from. Hercules. This raw material is an already pre-dissolved cationic guar derivative. The cationic guar derivatives are preferred according to the invention.
  • a suitable chitosan is sold, for example, by Kyowa Oil & Fat, Japan under the trade name Flonac ®.
  • a preferred chitosan salt is
  • Chitosoniumpyrrolidoncarboxylat which is sold for example under the name Kytamer ® PC by Amerchol, USA.
  • Further chitosan derivatives are Hydagen® ® CMF, Hydagen® ® HCMF and Chitolam ® NB / 101 freely available under the trade names in the trade.
  • cationic polymers based on sugars can also be used according to the invention with preference.
  • Such compounds are, for example, cationic alkyl oligoglucosides as shown in the following figure.
  • the radicals R independently of one another are a linear or branched C 6 to C 30 alkyl radical, a linear or branched C 6 -C 30 alkenyl radical, preferably the radical R is a radical R selected from: lauryl, myristyl, cetyl, stearyl, Oleyl, behenyl or arachidyl.
  • the radicals R 1 independently of one another are a linear or branched C 6 to C 30 alkyl radical, a linear or branched C 6 to C 30 alkenyl radical, preferably the radical R is a radical selected from: butyl, capryl, caprylyl, octyl, nonyl, decanyl, lauryl, Myristyl, cetyl, stearyl, oleyl, behenyl or arachidyl. More preferably, the radicals R1 are the same.
  • the radicals R1 are selected from technical mixtures of the fatty alcohol cuts of C6 / C8 fatty alcohols, C8 / C10 fatty alcohols, C10 / C12 fatty alcohols, C12 / C14 fatty alcohols, C12 / C18 fatty alcohols, and most preferred are those technical Fatty alcohol cuts of plant origin.
  • cationic alkyl oligoglucosides are the compounds having the INCI names Polyquaternium-77, Polyquaternium-78, Polyquaternium-79, Polyquaternium-80, Polyquaternium-81 and Polyquaternium-82. Most preferred are the cationic alkyl oligoglucosides designated Polyquaternium-77, Polyquaternium-81 and Polyquaternium-82.
  • Such compounds can be obtained, for example, under the name Poly Suga® Quat from the company Colonial Chemical Inc.
  • the cationic alkyl oligoglucosides are used in a total amount of from 0.01 to 10.0% by weight, preferably from 0.05 to 5.0% by weight, more preferably from 0.1 to 3.0% by weight, and most preferably in amounts from 0.2 to 2.0% by weight, based in each case on the total weight of the composition.
  • mixtures of cationic alkyl oligoglucosides can be used. In this case, preference is given to using one long-chain and one short-chain cationic alkyl oligoglucoside at the same time.
  • Another cationic polymer can be obtained based on ethanolamine.
  • the polymer is commercially available under the name Polyquaternium-71.
  • This polymer can be obtained, for example, under the name Cola® Moist 300 P from Colonial Chemical Inc.
  • amphoteric polymers are copolymers of at least one monomer (Mono1) or (Mono2) with the monomer (Mono3), in particular copolymers of the monomers (Mono2) and (Mono3).
  • amphoteric polymers are copolymers of diallyl dimethyl ammonium chloride and acrylic acid. These copolymers are sold under the INCI name Polyquaternium-22, among others, with the trade name Merquat ® 280 (Nalco).
  • Amphoteric polymers based on a comonomer (Mono4) which are very particularly preferably used according to the invention are terpolymers of diallyldimethylammonium chloride, acrylamide and acrylic acid. These copolymers are marketed ® under the INCI name Polyquaternium-39, among others, with the trade name Merquat Plus 3330 (Nalco).
  • amphoteric polymers can generally be used both directly and in salt form, which is obtained by neutralization of the polymers, for example with an alkali metal hydroxide, according to the invention.
  • the abovementioned cationic polymers can be used individually or in any desired combinations with one another, with amounts of from 0.01 to 10% by weight, preferably from 0.01 to 7.5% by weight, and very particularly preferably from 0 to 0, 1 to 5.0% by weight are included. The very best results are obtained with amounts of from 0.1 to 3.0% by weight, based in each case on the total composition of the particular agent.
  • the agents according to the invention preferably contain at least one silicone polymer selected from the group of dimethiconols and / or the group of amino-functional silicones and / or the group of dimethicones and / or the group of cyclomethicones.
  • silicone polymer selected from the group of dimethiconols and / or the group of amino-functional silicones and / or the group of dimethicones and / or the group of cyclomethicones.
  • arylated silicones of the respective groups of silicones are not included in the compositions of the invention.
  • the dimethicones according to the invention can be both linear and branched as well as cyclic or cyclic and branched.
  • Linear dimethicones can be represented by the following structural formula (Si1): (SiR 1 3 ) - O - (SiR 2 2 - O -) x - (SiR 1 3 ) (Si 1 )
  • Branched dimethicones can be represented by the structural formula (Si1.1):
  • the radicals R 1 and R 2 are each independently hydrogen, a methyl radical, a C 2 to C 30 linear, saturated or unsaturated hydrocarbon radical, a phenyl radical and / or an aryl radical.
  • the numbers x, y and z are integers and each run independently from 0 to 50,000.
  • the molecular weights of the dimethicones are between 1000 D and 10,000,000 D.
  • the viscosities are between 100 and 10,000,000 cPs measured at 25 ° C. with the aid of a glass capillary viscometer according to the Dow Corning Corporate Test Method CTM 0004 of 20 July 1970.
  • Preferred viscosities are between 1,000 and 5,000,000 cPs, most preferred viscosities are between 10,000 and 3,000,000 cps.
  • the most preferred range is between 50,000 and 2,000,000 cps. Most preferred are viscosities around the range of about 60,000 cps.
  • Particularly preferred cosmetic or dermatological preparations according to the invention are characterized in that they contain at least one silicone of the formula (Si1.2) (CH 3 ) 3 Si [O-Si (CH 3 ) 2 ] x -O-Si (CH 3 ) 3 (Si 1.2), in which x is a number from 0 to 100, preferably from 0 to 50, more preferably from 0 to 20 and in particular 0 to 10.
  • the dimethicones (Si1) are present in the compositions according to the invention in amounts of from 0.01 to 10% by weight, preferably from 0.01 to 8% by weight, particularly preferably from 0.1 to 7.5% by weight and in particular from 0.1 to 5 wt.% Based on the total composition.
  • silicone compounds Dimethiconole (Si8) understood.
  • the dimethiconols according to the invention can be both linear and branched as well as cyclic or cyclic and branched.
  • Linear dimethiconols can be represented by the following structural formula (Si8-I): (SiOHR 1 2 ) - O - (SiR 2 2 - O -) x - (SiOHR 1 2 ) (Si 8 - I)
  • Branched dimethiconols can be represented by the structural formula (Si8 - II):
  • the radicals R 1 and R 2 are each independently hydrogen, a methyl radical, a C 2 to C 30 linear, saturated or unsaturated hydrocarbon radical.
  • the numbers x, y and z are integers and each run independently from 0 to 50,000.
  • the molecular weights of the dimethiconols are between 1000 D and 10,000,000 D.
  • the viscosities are between 100 and 10,000,000 cPs measured at 25 ° C. with the aid of a glass capillary viscometer according to the Dow Corning Corporate Test Method CTM 0004 of 20 July 1970.
  • Preferred viscosities are between 1,000 and 5,000,000 cPs, most preferred viscosities are between 10,000 and 3,000,000 cps. The most preferred range is between 50,000 and 2,000,000 cps.
  • Examples of such products include the following commercial products: Dow Coming 1-1254 Fluid, Dow Corning 2-9023 Fluid, Dow Coming 2-9026 Fluid, Abil OSW 5 (Degussa Care Specialties), Dow Coming 1401 Fluid, Dow Coming 1403 Fluid Dow Corning 1501 Fluid, Dow Corning 1784 HVF Emulsion, Dow Corning 9546 Silicone Elastomer Blend, SM555, SM2725, SM2765, SM2785 (all four aforementioned GE Silicones), Wacker-Belsil CM 1000, Wacker-Belsil CM 3092, Wacker-Belsil CM 5040, Wacker-Belsil DM 3096, Wacker-Belsil DM 3112 VP, Wacker-Belsil DM 8005 VP, Wacker-Belsil DM 60081 VP (all Wacker-Chemie GmbH mentioned above).
  • the dimethiconols (Si8) are present in the compositions according to the invention in amounts of from 0.01 to 10% by weight, preferably from 0.01 to 8% by weight, more preferably from 0.1 to 7.5% by weight and in particular from 0.1 to 5% by weight of dimethiconol based on the composition.
  • Particularly preferred agents according to the invention contain one or more amino-functional silicones.
  • Such silicones may be represented, for example, by the formula (Si-2) M (R a Q b SiO (4-ab) / 2 ) x (R c SiO (4-c) / 2 ) y M (Si-2)
  • Z is according to formula (Si-2) an organic, amino-functional radical containing at least one functional amino group.
  • a possible formula for said Z is NH (CH 2 ) z NH 2 , where z is an integer greater than or equal to 1.
  • Another possible formula for said Z is -NH (CH 2 ) z (CH 2 ) zz NH, wherein both z and zz independently of one another are an integer greater than or equal to 1, this structure comprising diamino ring structures, such as piperazinyl.
  • Said Z is most preferably an -NHCH 2 CH 2 NH 2 radical.
  • Z is -N (CH 2 ) z (CH 2 ) zz NX 2 or -NX 2 , wherein each X of X 2 is independently selected from the group consisting of hydrogen and alkyl groups of 1 to 12 carbon atoms, and zz is 0.
  • Q according to formula (Si-2) is most preferably a polar amino-functional radical of formula - CH 2 CH 2 CH 2 NH 2 CH 2 CH 2 NH 2 .
  • ⁇ assumes values in the range of 0 to 2
  • b takes values in the range of 2 to 3
  • a + b is less than or equal to 3
  • c is a number in the range of 1 to 3.
  • cationic silicone oils such as, for example, the commercially available products Dow Corning (DC) 929 emulsion, DC 2-2078, DC 5-7113, SM-2059 (General Electric) and SLM-55067 (Wacker).
  • Particularly preferred agents according to the invention are characterized in that they contain at least one amino-functional silicone of the formula (Si 3-a) in which m and n are numbers whose sum (m + n) is between 1 and 2000, preferably between 50 and 150, where n preferably values of 0 to 1999 and in particular of 49 to 149 and m preferably values of 1 to 2000 , in particular from 1 to 10 assumes.
  • Si 3-a amino-functional silicone of the formula (Si 3-a) in which m and n are numbers whose sum (m + n) is between 1 and 2000, preferably between 50 and 150, where n preferably values of 0 to 1999 and in particular of 49 to 149 and m preferably values of 1 to 2000 , in particular from 1 to 10 assumes.
  • silicones are referred to as trimethylsilylamodimethicones according to the INCI declaration and are available, for example, under the name Q2-7224 (manufacturer: Dow Corning, a stabilized trimethylsilylamodimethicone).
  • silicones are according to the INCI declaration as Amodimethicone, or as functionalized Amodimethicone, such as bis (C13-15 alkoxy) PG Amodimethicone (for example, as a commercial product: DC 8500 from Dow Corning available), trideceth-9 PG-amodimethicones (for example as the commercial product Silcare Silicone SEA available from Clariant).
  • Amodimethicone or as functionalized Amodimethicone, such as bis (C13-15 alkoxy) PG Amodimethicone (for example, as a commercial product: DC 8500 from Dow Corning available), trideceth-9 PG-amodimethicones (for example as the commercial product Silcare Silicone SEA available from Clariant).
  • Suitable diquaternary silicones are selected from compounds of the general formula (Si3c) [R 1 R 2 R 3 N + -A-SiR 7 R 8 - (O-SiR 9 R 10 ) n -O-SiR 11 R 12 -A-N + R 4 R 5 R 6 ] 2X - (Si 3c) where the radicals R 1 to R 6 independently of one another are C 1 to C 22 -alkyl radicals which may contain hydroxyl groups and where preferably at least one of the radicals has at least 8 C atoms and the remaining radicals have 1 to 4 C atoms, the radicals R 7 to R 12 are each independently the same or different and are C1 to C10 alkyl, A is a divalent organic compound group, n is a number from 0 to 200, preferably from 10 to 120, more preferably from 10 to 40, and X - is an anion.
  • the divalent linking group is preferably a C1 to C12 alkylene or alkoxyalkylene group which may be substituted with one or more hydroxyl groups. Particularly preferred is the group - (CH 2 ) 3 -O-CH 2 -CH (OH) -CH 2 -.
  • the anion X - can be a halide ion, an acetate, an organic carboxylate or a compound of the general formula RSO 3 - , wherein R has the meaning of C1 to C4 alkyl radicals.
  • a preferred diquaternary silicone has the general formula (Si3d) [RN + Me 2 -A- (SiMe 2 O) n -SiMe 2 -A-N + Me 2 R] 2 CH 3 COO - (Si 3d), where A is the group - (CH 2 ) 3 - O - CH 2 - CH (OH) - CH 2 -,
  • R is an alkyl radical having at least 8 C atoms and n is a number from 10 to 120.
  • Suitable silicone polymers having two terminal quaternary ammonium groups are known under the INCI name Quaternium-80. These are dimethylsiloxanes with two terminal trialkylammonium groups. Such diquaternary polydimethylsiloxanes are marketed by Evonik under the trade names Abil ® Quat 3270, 3272 and 3474th Hair treatment compositions which are preferred according to the invention are characterized in that, based on their weight, they contain 0.01 to 10% by weight, preferably 0.01 to 8% by weight, particularly preferably 0.1 to 7.5% by weight and in particular 0, 2 to 5 wt.% Amino-functional silicone (s) and / or diquaternary silicone included.
  • polyammonium-polysiloxane compounds are polyammonium-polysiloxane compounds.
  • the polyammonium-polysiloxane compounds may be obtained for example under the trade name Baysilone® ® GE Bayer Silicones.
  • Baysilone TP 3911, SME 253 and SFE 839 are preferred. Very particular preference is given to the use of Baysilone TP 3911 as the active component of the compositions according to the invention.
  • the polyammonium-polysiloxane compounds are present in the compositions according to the invention in an amount of from 0.01 to 10% by weight, preferably from 0.01 to 7.5, particularly preferably from 0.01 to 5.0% by weight, very particularly preferably from 0 , 05 to 2.5 wt.% Each used in relation to the total composition.
  • the EP 1887024 A1 describes novel cationic amino-functional silicones which in particular improve the gloss in agents for the care of surfaces, for example human hair.
  • These cationic silicone polymers are characterized in that they have a silicone backbone and at least one polyether part and furthermore at least one part with an ammonium structure.
  • Examples of the preferred cationic silicone polymers in the context of the present invention are, in addition to the compounds of the aforementioned EP 1887024 A1 especially the compounds with the INCI names: Silicone Quaternium-1, Silicone Quaternium-2, Silicone Quaternium-3, Silicone Quaternium-4, Silicone Quaternium-5, Silicone Quaternium-6, Silicone Quaternium-7, Silicone Quaternium-8, Silicone Quaternium-9, Silicone Quaternium-10, Silicone Quaternium-11, Silicone Quaternium-12, Silicone Quaternium-15, Silicone Quaternium-16, Silicone Quaternium-17, Silicone Quaternium-18, Silicone Quaternium-20, Silicone Quaternium-21, Silicone Quaternium-22 as well as Silicone Quaternium-2 Panthenol Succinate and Silicone Quaternium-16 / Glycidyl Dimethicone Crosspolymer. Most preferred is Silicone Quaternium-22. This raw material is sold
  • the cationic amino-functional silicone polymers are present in the compositions according to the invention in amounts of from 0.01 to 20% by weight, preferably in amounts of from 0.05 to 10% by weight and very particularly preferably in amounts of from 0.1 to 7.5% by weight. contain. The very best results are obtained with amounts of from 0.1 to 5% by weight, based in each case on the total composition of the particular agent.
  • cyclic dimethicones designated as cyclomethicones according to INCI are also preferably used according to the invention.
  • cosmetic or dermatological preparations according to the invention which contain at least one silicone of the formula (Si-4) in which x is a number from 3 to 200, preferably from 3 to 10, more preferably from 3 to 7 and in particular 3, 4, 5 or 6 stands.
  • Agents which are likewise preferred according to the invention are characterized in that they contain at least one silicone of the formula (Si-5) R 3 Si [O-SiR 2 ] x - (CH 2 ) n - [O-SiR 2 ] y -O-SiR 3 (Si-5), in which R is identical or different radicals from the group -H, the C 1-20 -alkyl radicals, preferably -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH (CH 3 ) 2 , -CH 2 CH 2 CH 2 H 3 , -CH 2 CH (CH 3 ) 2 , --CH (CH 3 ) CH 2 CH 3 , -C (CH 3 ) 3 , x and y are each a number of 0 to 200, preferably from 0 to 10, more preferably from 0 to 7 and especially 0, 1, 2, 3, 4, 5 or 6, and n is a number from 0 to 10, preferably from 1 to 8 and especially
  • water-soluble silicones may be present in the compositions according to the invention.
  • Corresponding hydrophilic silicones are selected, for example, from the compounds of the formulas (Si-6) and / or (Si-7).
  • Particularly preferred water-soluble silicone-based surfactants are selected from the group of dimethicone copolyols which are preferably alkoxylated, in particular polyethoxylated or polypropoxylated.
  • Dimethicone copolyols are understood according to the invention as meaning preferably polyoxyalkylene-modified dimethylpolysiloxanes of the general formulas (Si-6) or (Si-7): in which the radical R represents a hydrogen atom, an alkyl group having 1 to 12 C atoms, an alkoxy group having 1 to 12 C atoms or a hydroxyl group, the radicals R 'and R "denote alkyl groups having 1 to 12 C atoms, x is an integer from 1 to 100, preferably from 20 to 30, y is an integer from 1 to 20, preferably from 2 to 10, and a and b are integers from 0 to 50, preferably from 10 to 30 ,
  • dimethicone copolyols according to the invention are, for example, the products sold commercially under the trade names SILWET (Union Carbide Corporation) and DOW CORNING.
  • Particularly preferred dimethicone copolyols according to the invention are Dow Corning 190 and Dow Corning 193.
  • the dimethicone copolyols are present in the compositions according to the invention in amounts of from 0.01 to 10% by weight, preferably from 0.01 to 8% by weight, more preferably from 0.1 to 7.5% by weight and in particular from 0.1 to 5% by weight. % of dimethicone copolyol based on the composition.
  • ester oil Another nourishing ingredient which may be used with particular preference is an ester oil.
  • Ester oils are preferred over the silicone oils in the preferred compositions of this invention.
  • the ester oils are defined as follows:
  • Ester oils are to be understood as meaning the esters of C 6 - C 30 fatty acids with C 2 - C 30 fatty alcohols.
  • the monoesters of the fatty acids with alcohols having 2 to 24 carbon atoms are preferred.
  • Examples of fatty acid components used in the esters are caproic acid, caprylic acid, 2-ethylhexanoic acid, capric acid, lauric acid, isotridecanoic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, elaidic acid, petroselinic acid, linoleic acid, linolenic acid, elaeostearic acid, arachidic acid, gadoleic acid, behenic acid and Erucic acid and its technical mixtures.
  • fatty alcohol components in the ester oils are isopropyl alcohol, caproic alcohol, capryl alcohol, 2-ethylhexyl alcohol, capric alcohol, lauryl alcohol, isotridecyl alcohol, myristyl alcohol, cetyl alcohol, palmoleyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, elaidyl alcohol, petroselinyl alcohol, linolyl alcohol, linolenyl alcohol, elaeostearyl alcohol, arachyl alcohol, gadoleyl alcohol, Behenyl alcohol, erucyl alcohol and brassidyl alcohol and their technical mixtures.
  • isopropyl myristate IPM Rilanit ®
  • isononanoic acid C16-18 alkyl ester Cetiol ® SN
  • 2-ethylhexyl palmitate Cegesoft ® 24
  • stearic acid-2-ethylhexyl ester Cetiol ® 868
  • cetyl oleate glycerol tricaprylate, Kokosfettalkohol- caprate / caprylate (Cetiol ® LC)
  • n-butyl stearate oleyl erucate
  • isopropyl palmitate IPP Rilanit ®
  • oleyl Oleate Cetiol ®
  • hexyl laurate Cetiol ® A
  • di-n-butyl adipate Cetiol ® B
  • myrist IPM Rilanit ®
  • ester oils may also be alkoxylated with ethylene oxide, propylene oxide, or mixtures of ethylene oxide and propylene oxide.
  • the alkoxylation can be found both on the fatty alcohol part and on the fatty acid part and on both parts of the ester oils.
  • R 1 is a saturated or unsaturated, branched or unbranched, cyclic saturated cyclic unsaturated acyl radical having 6 to 30 carbon atoms,
  • AO is ethylene oxide, propylene oxide or butylene oxide
  • X is a number between 1 and 200, preferably 1 and 100, more preferably between 1 and 50, most preferably between 1 and 20, most preferably between 1 and 10 and most preferably between 1 and 5,
  • R 2 represents a saturated or unsaturated, branched or unbranched, cyclic saturated cyclic unsaturated alkyl, alkenyl, alkynyl, phenyl or benzyl radical having from 6 to 30 carbon atoms.
  • fatty acid moieties used as radical R1 in the esters are caproic acid, caprylic acid, 2-ethylhexanoic acid, capric acid, lauric acid, isotridecanoic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, elaidic acid, petroselinic acid, linoleic acid, linolenic acid, elaeostearic acid, arachidic acid, gadoleic acid , Behenic acid and erucic acid and their technical mixtures.
  • fatty alcohol moieties R2 in the ester oils are benzyl alcohol, isopropyl alcohol, caproic alcohol, capryl alcohol, 2-ethylhexyl alcohol, capric alcohol, lauryl alcohol, isotridecyl alcohol, myristyl alcohol, cetyl alcohol, palmoleyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, elaidyl alcohol, petroselinyl alcohol, linolyl alcohol, linolenyl alcohol, elaeostearyl alcohol , Arachyl alcohol, gadoleyl alcohol, behenyl alcohol, erucyl alcohol and brassidyl alcohol and their technical mixtures.
  • a particularly preferred ester oil according to the invention is obtainable, for example, under the INCI name PPG-3 benzyl ether myristate.
  • Petroselinic acid linoleic acid, linolenic acid, elaeostearic acid, arachidic acid, gadoleic acid, behenic acid and erucic acid and their technical mixtures.
  • oleic acid monoglycerides are used.
  • the ester oils are present in the compositions according to the invention in an amount of from 0.01 to 20% by weight, preferably from 0.01 to 10.0% by weight, particularly preferably from 0.01 to 7.5% by weight, most preferably from 0, 1 to 5.0 wt.% Used.
  • natural oils for example, amaranth seed oil, apricot kernel oil, argan oil, avocado oil, babassu oil, cottonseed oil, borage seed oil, camelina oil, thistle oil, peanut oil, pomegranate seed oil, grapefruit seed oil, hemp oil, hazelnut oil, elderflower seed oil, currant seed oil, jojoba oil, cocoa butter, linseed oil, macadamia nut oil, corn oil, almond oil, marula oil , Evening primrose oil, olive oil, palm oil, rapeseed oil, rice oil, sea buckthorn pulp oil, sea buckthorn seed oil, sesame oil, shea butter, soybean oil, sunflower oil, grapeseed oil, walnut oil or wild rose oil.
  • natural oils for example, amaranth seed oil, apricot kernel oil, argan oil, avocado oil, babassu oil, cottonseed oil, borage seed oil, camelina oil, thistle oil, peanut oil, pomegranate seed oil, grapefruit
  • Amaranth seed oil apricot kernel oil, argan oil, marula oil, macadamia oil, almond oil, in particular sweet almond oil, sesame oil, sunflower oil, olive oil, orange oil, cape pine oil, wheat germ oil, peach kernel oil, isopropyl myristates, dicaprylyl carbonates and / or coco-caprylates and mixtures thereof are particularly preferred from the aforementioned ester oils.
  • ester oils are present in the compositions according to the invention in an amount of from 0.01 to 20% by weight, preferably from 0.01 to 10.0% by weight, particularly preferably from 0.01 to 7.5% by weight, most preferably from 0.1 to 5.0 wt.% Used.
  • the hair treatment compositions according to the invention also contain, in addition to the combination of active substances according to the invention, further constituents customary in cosmetic compositions.
  • the selection of these ingredients generally depends on the intended use of the hair treatment compositions.
  • a shampoo will be
  • further surface-active substances In the case of hair treatments, further cationic compounds and other care substances may be present.
  • the agents contain at least one surface-active substance, with both anionic and zwitterionic, ampholytic, nonionic and cationic surface-active substances being suitable in principle.
  • the choice of surfactants depends on the nature of the agent.
  • the mild anionic surfactants contain polyglycol ether chains, it is particularly preferred that they have a narrow homolog distribution. Furthermore, in the case of mild anionic surfactants having polyglycol ether units, it is preferred that the number of glycol ether groups is 1 to 20, preferably 2 to 15, more preferably 2 to 12. Particularly mild anionic surfactants having polyglycol ether groups without limited homolog distribution can be obtained, for example on the one hand the number of polyglycol ether groups is 4 to 12 and Zn or Mg ions are selected as the counterion. One example is the commercial product Texapon.RTM ® ASV.
  • Particularly suitable zwitterionic surfactants are the so-called betaines such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyl dimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and 2-alkyl-3-carboxymethyl 3-hydroxyethyl-imidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group and cocoacylaminoethylhydroxyethylcarboxymethylglycinate.
  • a preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine.
  • Ampholytic surfactants are understood as meaning those surface-active compounds which are capable of forming internal salts.
  • suitable ampholytic surfactants are N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 24 C Atoms in the alkyl group.
  • amphoteric or zwitterionic surfactants are alkylbetaines, alkylamidobetaines, aminopropionates, aminoglycinates, imidazolinium betaines and sulfobetaines.
  • Particularly preferred ampholytic surfactants are N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate and C 12 -C 18 acylsarcosine.
  • Cationic surfactants of the formula (Tkat1-1) can additionally be used.
  • R1, R2, R3 and R4 each independently represent hydrogen, a methyl group, a phenyl group, a benzyl group, a saturated, branched or unbranched alkyl group having a chain length of 8 to 30 carbon atoms, optionally with one or more hydroxy groups may be substituted.
  • A is a physiologically acceptable anion, for example halides such as chloride or bromide and methosulfates.
  • Examples of compounds of formula (Tkat1) are lauryltrimethylammonium chloride, cetyltrimethylammonium chloride, cetyltrimethylammonium bromide, cetyltrimethylammonium methosulfate, dicetyldimethylammonium chloride, tricetylmethylammonium chloride, stearyltrimethylammonium chloride, distearyldimethylammonium chloride, lauryldimethylbenzylammonium chloride, behenyltrimethylammonium chloride, behenyltrimethylammonium bromide, behenyltrimethylammonium methosulfate.
  • the surfactants (T) are used in amounts of 0.05-45% by weight, preferably 0.1-30% by weight and very particularly preferably 0.5-25% by weight, based on the total agent used according to the invention ,
  • the agents according to the invention preferably contain the emulsifiers in amounts of 0.1-25% by weight, in particular 0.5-15% by weight, based on the total agent.
  • compositions according to the invention contain fatty substances (fat) as further active ingredient.
  • Fat substances (fat) are understood to mean fatty acids, fatty alcohols, natural and synthetic waxes, which can be in solid form as well as liquid in aqueous dispersion, and natural and synthetic cosmetic oil components.
  • fatty acids can be used linear and / or branched, saturated and / or unsaturated fatty acids having 6 to 30 carbon atoms. Preference is given to fatty acids having 10 to 22 carbon atoms. Among these could be mentioned, for example, isostearic as the commercial products Emersol ® 871 and Emersol ® 875, and isopalmitic acids such as the commercial product Edenor ® IP 95, and all other products sold under the trade names Edenor ® (Cognis) fatty acids.
  • fatty acids are caproic, caprylic, 2-ethylhexanoic, capric, lauric, isotridecanoic, myristic, palmitic, palmitoleic, stearic, isostearic, oleic, elaidic, petroselic, linoleic, linolenic as well as their technical mixtures.
  • Particularly preferred are usually the fatty acid cuttings obtainable from coconut oil or palm oil; In particular, the use of stearic acid is usually preferred.
  • the amount used is 0.1 - 15 wt.%, Based on the total mean.
  • the amount is preferably 0.5-10% by weight, with amounts of 1-5% by weight being particularly advantageous.
  • fatty alcohols fatal
  • saturated, mono- or polyunsaturated, branched or unbranched fatty alcohols with C 6 -C 30 -, preferably C 10 -C 22 -and very particularly preferably C 12 -C 22 -carbon atoms.
  • Decanols, octanols, dodecadienol, decadienol, oleyl alcohol, eruca alcohol, ricinoleic alcohol, stearyl alcohol, isostearyl alcohol, cetyl alcohol, lauryl alcohol, myristyl alcohol, arachidyl alcohol, caprylic alcohol, capric alcohol, linoleyl alcohol, linolenyl alcohol and behenyl alcohol are, for example, decanol, octanolol, dodecadienol, decadienol , as well as their Guerbet alcohols, this list should have exemplary and non-limiting character.
  • the fatty alcohols are derived from preferably natural fatty acids, which can usually be based on recovery from the esters of fatty acids by reduction. Can be used according to the invention also such fatty alcohol cuts, which represent a mixture of different fatty alcohols.
  • Such substances are, for example, under the names Stenol ® such as Stenol ® 1618 or Lanette ® such as Lanette ® O or Lorol ®, for example, Lorol ® C8, Lorol C14 ®, Lorol C18 ®, ® Lorol C8-18, HD-Ocenol ®, Crodacol ® such as Crodacol ® CS, Novol ®, Eutanol ® G, Guerbitol ® 16, Guerbitol ® 18, Guerbitol ® 20, Isofol ® 12, Isofol ® 16, Isofol ® 24, Isofol ® 36, Isocarb ® 12, Isocarb ® 16 or acquire
  • wool wax alcohols as are commercially available, for example under the names of Corona ®, White Swan ®, Coronet ® or Fluilan ® can be used according to the invention.
  • the fatty alcohols are used in amounts of from 0.1 to 30% by weight, based on the total preparation, preferably in amounts of from 0.1 to 20% by weight.
  • waxes As natural or synthetic waxes (Fatwax), solid paraffins or isoparaffins, carnauba waxes, beeswaxes, candelilla waxes, ozokerites, ceresin, spermaceti, sunflower wax, fruit waxes such as apple wax or citrus wax, microwaxes of PE or PP can be used according to the invention.
  • Such waxes are available, for example, from Kahl & Co., Trittau.
  • the amount used is 0.1-50 wt.% Based on the total agent, preferably 0.1 to 20 wt.% And particularly preferably 0.1 to 15 wt.% Based on the total agent.
  • the total amount of oil and fat components in the compositions according to the invention is usually 0.5-75% by weight, based on the total agent. Amounts of 0.5-35 wt .-% are preferred according to the invention.
  • vitamins are vitamins, provitamins or vitamin precursors.
  • Vitamins, pro-vitamins and vitamin precursors are particularly preferred, which are assigned to the groups A, B, C, E, F and H.
  • vitamin A includes retinol (vitamin A 1 ) and 3,4-didehydroretinol (vitamin A 2 ).
  • the ⁇ -carotene is the provitamin of retinol.
  • vitamin A component according to the invention for example, vitamin A acid and its esters, vitamin A aldehyde and vitamin A alcohol and its esters such as the palmitate and the acetate into consideration.
  • the agents according to the invention preferably contain the vitamin A component in amounts of 0.05-1% by weight, based on the total preparation.
  • Vitamin B 3 the compounds nicotinic acid and nicotinamide (niacinamide) are often performed.
  • Preferred according to the invention is the nicotinic acid amide which is contained in the agents used according to the invention preferably in amounts of from 0.05 to 1% by weight, based on the total agent.
  • Vitamin B 5 pantothenic acid, panthenol and pantolactone.
  • Panthenol and / or pantolactone are preferably used in the context of this group.
  • Derivatives usable according to the invention of panthenol are in particular the esters and ethers of panthenol and cationically derivatized panthenols. Individual representatives are, for example, panthenol triacetate, panthenol monoethyl ether and its monoacetate, as well as cationic panthenol derivatives.
  • Pantothenic acid is preferably used as a derivative in the form of the more stable calcium salts and sodium salts (Ca-pantothenate, Na-pantothenate) in the present invention.
  • Vitamin B 6 pyridoxine and pyridoxamine and pyridoxal.
  • the said compounds of the vitamin B type are preferably present in the agents according to the invention in amounts of 0.05-10% by weight, based on the total agent. Amounts of 0.1-5 wt .-% are particularly preferred.
  • Vitamin C (ascorbic acid). Vitamin C is used in the agents according to the invention preferably in amounts of 0.1 to 3 wt .-%, based on the total agent. Use in the form of palmitic acid ester, glucosides or phosphates may be preferred. The use in combination with tocopherols may also be preferred.
  • Vitamin E tocopherols, especially ⁇ -tocopherol.
  • Tocopherol and its derivatives which include in particular the esters such as the acetate, the nicotinate, the phosphate and the succinate, are preferably present in the agents according to the invention in amounts of 0.05-1% by weight, based on the total agent.
  • Vitamin F is usually understood as meaning essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid.
  • Vitamin H is the compound (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4-d] -imidazole-4-valeric acid, for which, however, the trivial name biotin has meanwhile become established.
  • Biotin is preferably present in the compositions according to the invention in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight.
  • compositions according to the invention preferably contain vitamins, provitamins and vitamin precursors from groups A, B, E and H. Panthenol, pantolactone, pyridoxine and its derivatives as well as nicotinic acid amide and biotin are particularly preferred.
  • a particularly preferred group of ingredients in the cosmetic compositions according to the invention are the betaines mentioned below: carnitine, carnitine tartrate, carnitine magnesium citrate, acetyl carnitine, betalain, 1,1-dimethyl-proline, choline, choline chloride, choline bitartrate, choline dihydrogen citrate and those described in the literature Betaine designated compound N, N, N-trimethylglycine.
  • Carnitine, histidine, choline and betaine are preferably used.
  • the active ingredient used is L-carnitine tartrate.
  • compositions according to the invention contain biochinones.
  • suitable biochinones are understood as meaning one or more ubiquinone (s) and / or plastoquinone (s).
  • the preferred ubiquinones according to the invention have the following formula:
  • Coenzyme Q-10 is most preferred.
  • compositions of the invention contain purine and / or purine derivatives in narrower ranges.
  • preferred cosmetic compositions according to the invention are characterized in that they contain, based on their weight, from 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, particularly preferably from 0.005 to 0.5% by weight and in particular from 0.01 to 0.1% by weight of purine (s) and / or purine derivative (s).
  • Cosmetic agents preferred according to the invention are characterized in that they contain purine, adenine, guanine, uric acid, hypoxanthine, 6-purinethiol, 6-thioguanine, xanthine, caffeine, theobromine or theophylline. In hair cosmetic preparations, caffeine is most preferred.
  • the cosmetic agent contains ectoine ((S) -2-methyl-1,4,5,6-tetrahydro-4-pyrimidinecarboxylic acid.)
  • agents which, based on their weight, are 0 , 00001 to 10.0 wt .-%, preferably 0.0001 to 5.0 wt .-% and in particular 0.001 to 3 wt .-% of the active ingredients from the group formed by carnitine, coenzyme Q-10, ectoine , a B-series vitamin, a purine and their derivatives or physiologically acceptable salts.
  • a particularly preferred care additive in the hair treatment compositions according to the invention is taurine.
  • Taurine is understood to mean exclusively 2-aminoethanesulfonic acid and a derivative to the explicitly mentioned derivatives of taurine.
  • Derivatives of taurine include N-monomethyltaurine, N, N-dimethyltaurine, tauryllysylate, taurine tartrate, taurine ornithithate, lysyltaurine and ornithyl taurine.
  • agents according to the invention which - based on their weight - 0.0001 to 10.0 wt .-%, preferably 0.0005 to 5.0 wt .-%, particularly preferably 0.001 to 2.0 wt .-% and In particular, 0.001 to 1.0 wt .-% taurine and / or a derivative of taurine included.
  • the effect of the compositions according to the invention can be further enhanced by a 2-pyrrolidinone-5-carboxylic acid and its derivatives (J).
  • the sodium salt is most preferred.
  • the amounts used in the inventive compositions are 0.05 to 10 wt.%, Based on the total agent, particularly preferably 0.1 to 5, and in particular 0.1 to 3 wt.%.
  • the hair treatment compositions according to the invention can be formulated in a particularly natural and yet very effective way in their care performance.
  • even otherwise customary preservatives can be dispensed with.
  • the plant extracts can be used according to the invention both in pure and in diluted form. If they are used in diluted form, they usually contain about 2 to 80 wt .-% of active substance and as a solvent used in their extraction agent or extractant mixture.
  • anionic polymers examples include acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid.
  • the acidic groups may be wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt.
  • Preferred monomers are 2-acrylamido-2-methylpropanesulfonic acid and acrylic acid.
  • Anionic polymers which contain 2-acrylamido-2-methylpropanesulfonic acid as the sole or co-monomer can be found to be particularly effective, it being possible for all or some of the sulfonic acid group to be present as sodium, potassium, ammonium, mono- or triethanolammonium salt ,
  • the homopolymer of 2-acrylamido-2-methylpropansulfon acid which is available for example under the name Rheothik ® 11-80 is commercially.
  • Preferred nonionic monomers are acrylamide, methacrylamide, acrylic esters, methacrylic esters, vinylpyrrolidone, vinyl ethers and vinyl esters.
  • Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with sulfonic acid-containing monomers. Such a polymer is contained in the commercial product Sepigel ® 305 from SEPPIC.
  • anionic homopolymers are uncrosslinked and crosslinked polyacrylic acids. Allyl ethers of pentaerythritol, sucrose and propylene may be preferred.
  • Be networking agents Such compounds are for example available under the trademark Carbopol ® commercially.
  • Copolymers of maleic anhydride and methyl vinyl ether, especially those with crosslinks, are also color-retaining polymers.
  • the anionic polymers are preferably contained in the agents according to the invention in amounts of from 0.05 to 10% by weight, based on the total agent. Amounts of 0.1 to 5 wt .-% are particularly preferred.
  • the agents according to the invention may contain nonionogenic polymers.
  • the nonionic polymers are preferably contained in the compositions according to the invention in amounts of from 0.05 to 10% by weight, based on the total agent. Amounts of 0.1 to 5 wt .-% are particularly preferred.
  • the agents according to the invention should additionally contain at least one UV light protection filter.
  • UVB filters can be oil-soluble or water-soluble.
  • UV-A filter in particular derivatives of benzoylmethane are suitable, such as 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1,3-dione or 1-phenyl-3 (4'-isopropylphenyl) -propane-1,3-dione.
  • the UV-A and UV-B filters can also be used in mixtures.
  • insoluble pigments are also suitable for this purpose, in particular finely dispersed metal oxides or salts, for example titanium dioxide, zinc oxide, iron oxide, aluminum oxide, cerium oxide, zirconium oxide, silicates (talc), barium sulfate and zinc stearate.
  • the particles should have an average diameter of less than 100 nm, preferably between 5 and 50 nm and in particular between 15 and 30 nm. They may have a spherical shape, but it is also possible to use those particles which have an ellipsoidal or otherwise deviating shape from the spherical shape.
  • Another subject of the invention is therefore a method for hair treatment, in which a hair treatment composition according to claim 1 is applied to the hair and is rinsed by the hair after a contact time.
  • the exposure time is preferably a few seconds to 100 minutes, more preferably 1 to 50 minutes and most preferably 1 to 30 minutes.
  • a cosmetic composition according to claim 1 is applied to the hair and remains there.
  • the agent is not rinsed out of the hair immediately after its application. Rather, the agent remains in this case more than 100 minutes until the next hair wash on the hair.
  • compositions were examined for conductivity.
  • the conductivity of W / O emulsions is significantly lower and approaches zero compared to O / W emulsions.
  • All emulsions according to the invention have proven to be W / O emulsions by this method.
  • the above compositions have a viscosity of between 600 and 40,000 mPas as measured by Brookfield at 25 ° C and with helipath.
  • All compositions can be filled in a standard bulk bottle or in pans. But they can also be provided in a corresponding pumping package with a conventional metering pump and packaged.
  • the dosing pump can of course contain a sieve, so that the compositions are applied as foam via the admixture of air in the pump head.
  • the filling in aerosol cans together with conventional propellants such as iso-propane, propane, isobutane, butane, tert-butane, pentane, iso-pentane, ter-pentane, neopentane or Dimethyl ether and any mixtures thereof in the ratio of 90: 10, preferably 92: 8 (blowing agent) possible.
  • propellants such as iso-propane, propane, isobutane, butane, tert-butane, pentane, iso-pentane, ter-pentane, neopentane or Dimethyl ether and any mixtures thereof in the ratio of 90: 10, preferably 92: 8 (blowing agent) possible.
  • a particularly creamy and stable foam is obtained, which can be very well distributed in the hair.
  • the performance assessment was carried out by 5 hairdressers on 20 heads each in the so-called half-page test.
  • the recipes E1 to E4 were tested against the recipes V1 to V4.
  • the formulations V1 to V4 are the formulations E1 to E4, however, without protein hydrolyzate and PEG-30 dipolyhydroxystearates, the combination of active substances according to the invention.
  • the hair was washed as usual with a shampoo and dried with a towel.
  • the head halves were parted with a comb in the middle and applied to each half of the head 5 g of the respective test composition, ie E1 vs. V1, etc.
  • the compositions were immersed under running water at about 32 ° C rinsed out again for 3 minutes. Subsequently, the comparative assessment was carried out by the 5 hairdressers.
  • compositions E1 to E4 according to the invention were found in the parameters of wet hair treatment with the hair dryer, combability, wet and dry hair feel, wet and dry hair tips, dry hair body and dry hair gloss at least 0, respectively , 67 notes better.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
EP12191940.1A 2011-12-19 2012-11-09 Procédé de soin capillaire avec un produit de soin comprenant un émulsifiant spécial et des hydrolysats protéiques Not-in-force EP2606936B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102011088929A DE102011088929A1 (de) 2011-12-19 2011-12-19 Haarkur mit einem speziellen Emulgator und Proteinhydrolysaten

Publications (3)

Publication Number Publication Date
EP2606936A2 true EP2606936A2 (fr) 2013-06-26
EP2606936A3 EP2606936A3 (fr) 2014-06-25
EP2606936B1 EP2606936B1 (fr) 2017-06-07

Family

ID=47143034

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12191940.1A Not-in-force EP2606936B1 (fr) 2011-12-19 2012-11-09 Procédé de soin capillaire avec un produit de soin comprenant un émulsifiant spécial et des hydrolysats protéiques

Country Status (2)

Country Link
EP (1) EP2606936B1 (fr)
DE (1) DE102011088929A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018059778A1 (fr) * 2016-09-30 2018-04-05 Henkel Ag & Co. Kgaa Produits de soin capillaire à effet de conditionnement amélioré assurant une protection contre la perte de couleur
WO2024200277A1 (fr) * 2023-03-24 2024-10-03 Byk-Chemie Gmbh Agent de couplage à base de protéine pour fibres de carbone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1887024A1 (fr) 2006-07-31 2008-02-13 Evonik Goldschmidt GmbH Polysiloxane d'un nouveau type doté de groupes d'ammonium quaternaires, son procédé de fabrication et son utilisation dans des formulation de nettoyage et de soin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4009617A1 (de) * 1990-03-26 1991-10-02 Henkel Kgaa Haarregenerierende zubereitungen
US6762158B2 (en) * 1999-07-01 2004-07-13 Johnson & Johnson Consumer Companies, Inc. Personal care compositions comprising liquid ester mixtures
ATE234598T1 (de) * 2000-01-19 2003-04-15 Kpss Kao Gmbh Haarpflegemulsion
DE10048366A1 (de) * 2000-09-29 2002-04-11 Beiersdorf Ag Zubereitungen vom Emulsionstyp W/O mit erhöhtem Wassergehalt, mit mittelpolaren und/oder unpolaren Lipiden und einem oder mehreren grenzflächenaktiven Polyethern vom Typ A-O-B-O-A sowie mit mindestens einer Substanz, gewählt aus der Gruppe der kationischen Polymere

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1887024A1 (fr) 2006-07-31 2008-02-13 Evonik Goldschmidt GmbH Polysiloxane d'un nouveau type doté de groupes d'ammonium quaternaires, son procédé de fabrication et son utilisation dans des formulation de nettoyage et de soin

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018059778A1 (fr) * 2016-09-30 2018-04-05 Henkel Ag & Co. Kgaa Produits de soin capillaire à effet de conditionnement amélioré assurant une protection contre la perte de couleur
WO2024200277A1 (fr) * 2023-03-24 2024-10-03 Byk-Chemie Gmbh Agent de couplage à base de protéine pour fibres de carbone

Also Published As

Publication number Publication date
DE102011088929A1 (de) 2013-06-20
EP2606936A3 (fr) 2014-06-25
EP2606936B1 (fr) 2017-06-07

Similar Documents

Publication Publication Date Title
EP2762127A1 (fr) Produit de soin capillaire doté de substances actives antipelliculaires et de tensioactifs cationiques végétaux sélectionnés
DE102010063590A1 (de) Haarbehandlungsmittel enthaltend Dicocoyl Pentaerythrityl Distearyl Citrate
EP2836276A2 (fr) Produit de soin capillaire contenant des polymères spéciaux
DE102009027964A1 (de) Haarkonditionierende Mittel mit ausgewählten kationischen Siliconen und Dimethicon
DE102012203240A1 (de) Haarpflegemittel mit Antischuppenmitteln und ausgewählten Aminosilikonen
DE102011086635A1 (de) Haarpflegemittel mit Antischuppenmitteln und kationischen Silikonen
EP2724710A2 (fr) Produit de soin capillaire comprenant des alkyloligoglucosides cationiques et des esters de polyglycérine
WO2011009710A2 (fr) Produits de conditionnement capillaire contenant des imidazolines cationiques et des silicones cationiques sélectionnées
DE102009044948A1 (de) Mittel zur Behandlung keratinischer Fasern enthaltend Dimethylsilanol Hyaluronate und Glycerin
DE102010063791A1 (de) Haarbehandlungsmittel enthaltend Copaifera Officinalis Oil, Bertholletia Excelsea Nut Oil und Antischuppenwirkstoffe
DE102010062639A1 (de) Haarbehandlungsmittel enthaltend Ximenia-Öl
DE102010062640A1 (de) Haarbehandlungsmittel enthaltend Mongongo-Öl
EP2606936B1 (fr) Procédé de soin capillaire avec un produit de soin comprenant un émulsifiant spécial et des hydrolysats protéiques
EP2822658A2 (fr) Produit de cure capillaire exempt de silicones arylées
EP2724714A2 (fr) Spray de soin clair doté d'une performance accrue
DE102010062638A1 (de) Haarbehandlungsmittel enthaltend Baobab-Öl
DE102009045997A1 (de) Haarbehandlungsmittel mit Polyquaternium-72
DE102009028537A1 (de) Zusammensetzungen zur Haarpflege enthaltend natürliche Öle mit hohen Anteilen gesättigter Fettsäuren
DE102013226423A1 (de) Haarbehandlungsmittel mit spezieller Konditioniermittelkombination
WO2013072156A2 (fr) Produit de soins capillaires contenant des composés cationiques sélectionnés et des silicones cationiques
DE102012214140A1 (de) Haarpflegemittel mit Antischuppenmitteln und ausgewählte Komplexe aus sauren Proteinhydrolysaten und basischen Fettsäureamidoaminen
DE102011085215A1 (de) Haarbehandlungsmittel enthaltend Kamutprotein
EP2825262A2 (fr) Produit de cure capillaire exempt de silicones arylées
DE102009027965A1 (de) Haarkonditionierende Mittel mit ausgewählten kationischen Siliconen und einem Vitamin der B-Reihe
DE102011085216A1 (de) Haarbehandlungsmittel enthaltend ausgewählte Gemüseextrakte

Legal Events

Date Code Title Description
17P Request for examination filed

Effective date: 20121115

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

RIC1 Information provided on ipc code assigned before grant

Ipc: A61Q 5/12 20060101AFI20140514BHEP

Ipc: A61K 8/49 20060101ALI20140514BHEP

Ipc: A61K 8/34 20060101ALI20140514BHEP

Ipc: A61K 8/92 20060101ALI20140514BHEP

Ipc: A61K 8/86 20060101ALI20140514BHEP

Ipc: A61K 8/81 20060101ALI20140514BHEP

Ipc: A61K 8/44 20060101ALI20140514BHEP

Ipc: A61K 8/37 20060101ALI20140514BHEP

Ipc: A61K 8/65 20060101ALI20140514BHEP

Ipc: A61K 8/64 20060101ALI20140514BHEP

Ipc: A61K 8/67 20060101ALI20140514BHEP

Ipc: A61K 8/41 20060101ALI20140514BHEP

Ipc: A61K 8/73 20060101ALI20140514BHEP

Ipc: A61K 8/06 20060101ALI20140514BHEP

Ipc: A61K 8/60 20060101ALI20140514BHEP

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

17Q First examination report despatched

Effective date: 20140625

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20170202

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 898765

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170615

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502012010482

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170607

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170907

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170908

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170907

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171007

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502012010482

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: DE

Ref legal event code: R084

Ref document number: 502012010482

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

26N No opposition filed

Effective date: 20180308

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171109

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20171130

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171130

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 898765

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20121109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170607

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20211122

Year of fee payment: 10

Ref country code: DE

Payment date: 20211118

Year of fee payment: 10

Ref country code: GB

Payment date: 20211119

Year of fee payment: 10

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 502012010482

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20221109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221109

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221130